天智航公告称，截至2026年1月8日收盘，先进制造产业投资基金（有限合伙）及其一致行动人京津冀产 业协同发展投资基金（有限合伙）持股比例由6.95%降至5.93%，权益变动触及1%整数倍。2025年12月9 日至2026年1月8日，先进制造基金减持232.14万股，占总股本0.51%；京津冀基金减持233.23万股，占 比0.51%。目前，减持计划尚未实施完毕。 ...

格隆汇1月8日丨先健科技(01302.HK)宣布，于2026年1月7日，公司自主研发的G-iliac™Pro髂动脉覆膜 支架系统(「G-iliac™Pro」)获中国国家药品监督管理局正式注册批准。该产品适用于腹主动脉瘤合并髂 动脉瘤或孤立髂总动脉瘤的腔内治疗，通过重建髂内动脉确保盆腔供血，为临床提供了更成熟、更完善 的解决方案，实现了对既有治疗方案的系统性升级。 髂内动脉为髂总动脉的重要分支，承担着盆腔脏器、臀肌及脊髓的重要供血功能。早期腹主动脉瘤腔内 修复术(「EVAR」)中，为了防止内漏往往会栓塞一侧或双侧髂内动脉，从而引发臀肌跛行、性功能障 碍、结肠缺血、直肠坏死、脊髓缺陷甚至截瘫等一系列并发症，严重影响患者长期生活质量。国内外大 量指南及共识已明确：EVAR术中，至少保留一侧髂内动脉，可使患者获得良好的预後。髂动脉分支支 架(「IBD」)技术，因其更符合生理解剖、内漏发生率低、远期通畅率高等优势，逐渐成为腔内重建髂 内动脉的理想选择。 ...

（股份代號：1302） 自願性公佈 香港交易及結算所有限公司與香港聯合交易所有限公司對本公佈的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示概不就因本公佈全部或任何部分內容而產生或因依賴該等內容 而引致的任何損失承擔任何責任。 LifeTech Scientific Corporation 先健科技公司 （在開曼群島註冊成立的有限公司） – 2 – G-iliacTM Pro髂動脈覆膜支架系統 獲得中國國家藥品監督管理局的正式註冊批准 本公佈乃由先健科技公司（「本公司」，連同其附屬公司稱為「本集團」）自願作出，旨 在向其股東及潛在投資者提供有關本集團最新業務及新產品開發情況的資料。 本公司董事（「董事」）會（「董事會」）欣然宣佈，於二零二六年一月七日，本公司自主 研發的G-iliacTM Pro髂動脈覆膜支架系統（「G-iliacTM Pro」或「該產品」）獲中國國家 藥品監督管理局（「國家藥品監督管理局」）正式註冊批准。該產品適用於腹主動脈瘤 合併髂動脈瘤或孤立髂總動脈瘤的腔內治療，通過重建髂內動脈確保盆腔供血，為 臨床提供了更成熟、更完善的解決方案，實現了對既有治療方案的系統性升級。 髂內 ...

Core Insights - The article highlights the emergence of Shenzhen-based Jingfeng Medical as a key player in the global surgical robot market, leveraging over 600 patents to reshape the competitive landscape dominated by foreign brands [1][2]. Company Overview - Jingfeng Medical, established in 2017, focuses on the design, research, and manufacturing of surgical robots, with a product matrix that includes multi-port and single-port laparoscopic surgical robots, as well as natural orifice surgical robots [2]. - The company is the first in China and the second globally to obtain regulatory approval for all three types of surgical robots, positioning its technology among the world's top tier [2]. Market Trends - The penetration rate of robotic-assisted laparoscopic surgery in China is currently low at 0.7% in 2024, with expectations to rise to 3.0% by 2033, compared to 21.9% in the U.S. in 2024, indicating significant growth potential for domestic companies like Jingfeng Medical [3]. Commercialization and Financial Performance - Jingfeng Medical began commercializing its multi-port laparoscopic surgical robot in December 2022, achieving a leading position in the domestic market with 20 units sold in 2024 [4]. - The company reported revenues of 48.04 million yuan in 2023, projected to increase to 160 million yuan in 2024, with a 400% year-on-year growth in the first half of 2025 [4][5]. - The revenue structure shows that 92.9% comes from surgical robot sales, with significant contributions from overseas markets, indicating successful global expansion [5]. Investment and Funding - Jingfeng Medical has raised over 2 billion yuan through six rounds of financing, attracting investments from notable institutions such as Sequoia China and Temasek [6]. - The recent IPO attracted a strong base of cornerstone investors, reflecting high market confidence in the company's technological capabilities and growth potential [6]. Competitive Landscape - The company has established a formidable competitive barrier with its complete product matrix of multi-port, single-port, and natural orifice surgical robots, being the only company in China and one of two globally to have all these products approved [8]. - The potential for high returns is emphasized, with expectations of continued growth driven by increased penetration of robotic-assisted surgeries and expansion into international markets [8].

成立至今20多年来，南微医学一直深耕内镜诊疗，通过自主研发和医工结合模式布局内镜诊疗器械、微波/射频消融设备及耗 材、一次性内镜等三大系列产品，在临床端加速国产化趋势。 在积极拓展国内市场的同时，南微医学坚定推进国际化战略。"目前，公司海外业务已拓展至美国、日本、欧洲、澳大利亚等90 多个国家和地区，2025年上半年海外营收占比达到58%。公司泰国生产基地预计将于2026年年初落成启用。"南微医学执行总裁 李常青近期接受21世纪经济报道记者专访时指出。 作为一位研发出身的技术带头人，李常青已肩负起"科学家+企业家"的双重责任，他从南微医学的实践出发，讲述了公司在内镜 诊疗器械领域从国内市场走向国际市场占比达六成的"出海"破局之道。 21世纪经济报道记者朱艺艺南京报道 南京市江北新区药谷大道199号，坐落着首批科创板上市企业、国内医疗器械龙头南微医学(688029.SH)。在这里，公司的三臂 夹、新一代胆道镜、支气管镜和热穿刺支架等一系列内镜诊疗领域的创新器械产品相继获得市场准入。 深耕内镜诊疗，力争创新产品占比30% 在2013年加入南微医学之前，李常青曾先后担任Sigma-Aldrich(默克)化工工程师、 ...

Group 1 - The core viewpoint is that China's innovative pharmaceuticals are strengthening their global competitiveness, with the past two years marking a significant period for international expansion and record-high licensing transactions in terms of quantity and value [1] - After the successful completion of business development (BD) transactions, the initiation of Phase III clinical trials overseas is expected to enhance the certainty of product listings, leading to an increase in valuations based on potential peak sales and improved success rates [1] - The domestic CRO (Contract Research Organization) orders are experiencing a trend of simultaneous growth in both volume and price, benefiting from the international expansion of innovative drugs and a stabilization in financing, with project volumes expected to achieve double-digit growth, indicating an improvement cycle in 2026 [1] Group 2 - In terms of overseas demand, China's CDMO (Contract Development and Manufacturing Organization) remains irreplaceable in the global supply chain, with steady growth in small molecule CDMO orders and rapid increases in orders for new molecular fields such as ADC (Antibody-Drug Conjugates) and peptides, with clinical and commercialization projects expected to gradually ramp up [1] - The medical device industry is accelerating innovation and internationalization, with an anticipated improvement in 2026, and a moderate trend in the collection policies for consumables and IVD (In Vitro Diagnostics), providing domestic manufacturers with opportunities for volume growth through price adjustments [1] - The Guotai Innovative Drug ETF (517110) tracks the SHS Innovative Drug Index (931409), which selects companies involved in the research and production of innovative drugs from both mainland and Hong Kong markets, covering 50 representative securities and focusing on the innovative drug industry chain [1]

微泰医疗-B(02235)发布公告，于2026年1月8日该公司斥资18.51万港元回购2.44万股，回购价格为每股 7.40-7.73港元。 ...

证券研究报告 | 公司深度报告 2026 年 01 月 08 日 先瑞达医疗-B（06669.HK） 波科赋能海外可期，新产品带来增长 消费品/生物医药 先瑞达是国内领先的专注于提供泛血管介入综合解决方案的创新医疗器械平台 型企业，率先于国内推出首款膝上及膝下 DCB 产品，在外周介入领域处于领先 地位；2025 年 12 月公司与控股股东波士顿科学签署新的三年期合作协议，在 产品全球商业化、制造服务和研发等领域开展一系列合作。 ❑ 与波科签署新三年期合作协议，海外放量确定性强。2023 年 2 月全球微创介 入医疗器械领先企业波士顿科学成为先瑞达控股股东，持股 65%，并于 2023 年 6 月签署首个合作谅解备忘录；2025 年 12 月，公司与波科签署新的三年 合作协议（2026-2028）：1）全球商业化：共享波科覆盖全球的渠道资源， 预计 2026-2028 年向波科销售产品交易金额上限为 3000/6200/7800 万美元； 2）产品制造：基于先瑞达智造能力提供产品 OEM 服务，预计 2026-2028 年 向波科提供制造服务交易金额上限为 100/100/300 万美元；3）产品研发：互 相 ...

Core Viewpoint - Weili Medical (603309.SH) announced that the sixth batch of national medical consumables procurement does not involve Wolf and Medical products, indicating a potential impact on the company's financials due to the acquisition of Wolf and Medical [2] Group 1: Financial Implications - The company has preliminarily assessed that goodwill arising from the acquisition of Wolf and Medical has shown signs of impairment based on the operational status projected for 2025 [2] - To reflect the financial status and asset value more objectively and fairly, the company plans to recognize goodwill impairment for the fiscal year 2025, with the final impairment amount to be determined by an evaluation and auditing firm [2] - The financial data for Q4 2025 has not yet been disclosed, and stakeholders are advised to pay attention to subsequent periodic reports for detailed descriptions and breakdowns of quarterly data [2] Group 2: Performance Forecast - The 2025 performance forecast data provided by the company is based on preliminary calculations from the finance department, with the accurate financial data to be confirmed in the officially disclosed audited annual report for 2025 [2]

出品｜搜狐财经 作者｜汪梦婷 编辑｜杨锦 2025年，A股总市值站上100万亿元的高峰，上证指数涨破4000点创下近十年新高。2026年A股市场又将如何演绎？哪些行业将孕育新的投资机遇？ 1月7日，创金合信全球医药生物（QDII）基金经理毛丁丁做客搜狐财经直播间，回顾了过去一年A股医药板块的结构性行情，并对2026年医药板块走势、投 资脉络进行了深度解析。 "2025年医药板块整体回暖，但结构性差异巨大。"毛丁丁分析指出，申万生物医药指数去年涨了约十个点，但仍跑输沪深300。创新药板块成为最大亮点， 而医疗器械、医疗服务等其他领域表现平平。 创新药板块的强势表现并非贯穿全年。毛丁丁指出，创新药主要在2025年3月至7月期间上涨，随后从9月开始持续回调至年底。这一调整主要由于二三季度 上涨过快、涨幅过大所致。 他分析道，恒生医疗保健、申万化学制药等代表性指数在去年8、9月份时，估值已超过历史估值中枢一倍标准差水平，需要时间消化前期涨幅。 搜狐财经《基金佳问》栏目特别推出"基遇2026"专题系列报道，复盘A股市场细分领域年内行情，展望及预测2026年各热门赛道的投资机遇，把握后市资产 配置的主逻辑，寻找具有投资潜 ...